• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

    3/6/25 1:36:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email

    PORTAGE, Mich., March 6, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its Artix Thrombectomy System. Purpose-built for the distinct needs of the peripheral arterial system, Artix is a combined aspiration plus mechanical thrombectomy solution that delivers procedural control and versatility, and is designed to set a new standard for arterial thrombectomy.

    Artix™ Thrombectomy System

    An arterial blood clot in the leg is a life- and limb-threatening emergency requiring immediate treatment. However, existing therapies for arterial thromboembolism can lead to:

    • Ineffective clot retrieval leading to additional procedures (open surgery or amputation1,2)
    • Significant blood loss1
    • Adverse events such as arterial embolization and vessel trauma2,3
    • High rates of lytic use, which may result in complications1,2

    The Artix System builds on the success of Inari's venous thrombectomy devices and is its inaugural entry into the arterial space. Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot.

    Jonathan Bowman, MD FACS, Chief of Vascular at Norwalk Hospital in Norwalk, CT, performed the first commercial case with Artix on October 19, 2024. "The Artix Thrombectomy System marks a significant advancement in peripheral arterial thromboembolism treatment," said Dr. Bowman. "With Artix, I finally have a solution that effectively addresses a wide range of clots while enabling me to maintain vessel access and retain control throughout the entire case. I expect Artix will take the place of open surgical repair in many of my arterial cases."

    Key distinctive features of the Artix system include:

    • Dual mechanical thrombectomy and aspiration toolkit designed to remove acute to chronic clots in a single session via a streamlined procedure4
    • Aspiration-capable, 8 Fr. low profile, trackable, kink-resistant sheath in both 65cm and 90cm lengths expands treatment options by enabling more complex and distal interventions
    • Innovative over-the-wire mechanical element designed to effectively collect and retrieve acute-to-chronic clot4
    • Covered nitinol mesh funnel provides temporary flow restriction during the procedure to minimize the risk of arterial clot migration5

    "There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy," said Tom Tu, MD, Chief Medical Officer of Inari Medical. "We are excited to bring Inari's core competency in thrombectomy to the arterial space with the goal of improving outcomes."

    For more information, visit https://www.inarimedical.com/artix-system

    About Stryker

    Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

    On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

    Media contact:

    Sherri Oakson

    Senior Director, Communications 

    MedSurg and Neurotechnology

    [email protected] 

    1. De Donato et al. The INDIAN Trial. Eur J Vasc Endovasc Surg. 2021; 61: 820-828.
    2. Heller et al. Percutaneous Mechanical Thrombectomy Using Rotarex Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International. 2017.
    3. Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019.
    4. Designed to remove acute to chronic arterial clots. According to benchtop testing compared to control. Internal data on file. Narula et al. JACC 2018;72:2153-63
    5. According to benchtop testing compared to control. Internal data on file. NOTE: To attempt to minimize risk of arterial embolization of blood clots, use of a device that entraps clots may potentially be helpful, but this has not yet been demonstrated to be effective in the arterial system.

    Dr. Jonathan Bowman is a paid consultant of Inari Medical. All views and opinions expressed here by Dr. Jonathan Bowman are his own and do not represent those of Inari Medical.

    Indications for Use: The Artix thin-walled sheath is indicated for: (1) The non-surgical removal of emboli and thrombi from blood vessels. (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. (3) Use as a conduit for endovascular devices. (4) Use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel. The funnel provides temporary vascular occlusion during these and other angiographic procedures. The Artix thin-walled sheath is intended for use in the peripheral vasculature. The Artix MT thrombectomy device is indicated for (1) the non-surgical removal of emboli and thrombi from a blood vessel; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix MT thrombectomy device is intended for use in the peripheral vasculature. The Artix AX aspiration catheter is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix AX aspiration catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Inari Medical catheters and sheaths for autologous blood transfusion.

    Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of these products.

    Stryker Logo (PRNewsfoto/Stryker)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inari-medical-now-part-of-stryker-launches-artix-thrombectomy-system-designed-to-address-a-broad-spectrum-of-arterial-thrombus-cases-302394987.html

    SOURCE Stryker

    Get the next $SYK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    SEC Filings

    View All

    SEC Form 10-Q filed by Stryker Corporation

    10-Q - STRYKER CORP (0000310764) (Filer)

    8/1/25 12:09:39 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STRYKER CORP (0000310764) (Filer)

    7/31/25 4:12:38 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Stryker Corporation

    S-8 - STRYKER CORP (0000310764) (Filer)

    5/30/25 4:16:27 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group President Menon Viju sold $195,305 worth of shares (500 units at $390.61), decreasing direct ownership by 4% to 12,511 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    8/27/25 4:32:36 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VP, Chief Legal Officer Fletcher Robert S sold $701,630 worth of shares (1,785 units at $393.07), decreasing direct ownership by 15% to 10,457 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    8/21/25 4:06:11 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Director Stryker Ronda E sold $75,289,655 worth of shares (200,000 units at $376.45) (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    8/7/25 4:36:56 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Stryker with a new price target

    Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

    2/26/25 7:17:53 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

    12/2/24 7:02:55 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stryker with a new price target

    Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

    9/10/24 8:01:33 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Financials

    Live finance-specific insights

    View All

    Stryker declares an $0.84 per share quarterly dividend

    Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more

    8/7/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports second quarter 2025 operating results

    Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 billionOrganic net sales increased 10.2%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 110 bps to 25.7%Reported EPS increased 7.0% to $2.29Adjusted EPS(1) increased 11.4% to $3.13  Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        17.3        %         0.6        %         16.7        %         5.7        %         11.0        %Orthopaedics   

    7/31/25 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.84 per share quarterly dividend

    Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

    5/8/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/12/24 10:18:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/14/23 12:37:55 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/10/23 9:18:16 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    View All

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

    Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

    1/28/25 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker to host investor day

    Portage, Michigan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Thursday, November 13, 2025, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey. A live audio webcast of the session, along with a replay, will be accessible on Stryker's official website at www.stryker.com. The recording will be archived on the Investor Relations section of the site. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our

    8/15/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference

    Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor. Andy Pierce, Group President, MedSurg and Neurotechnology, and Jason Beach, Vice President, Finance and Investor Relations will participate in a Fireside Chat scheduled for 2:15 pm Eastern Time. A live audio webcast of the session, along with a replay, will be accessible on Stryker's official website at www.stryker.com. The recording will be archived on the Investor Relations section of the site. About Stryker Stryker is a global leader in medical technologies and, together with our custo

    8/14/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.84 per share quarterly dividend

    Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more

    8/7/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care